Medical
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases
Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced that the first patient in the United States (US) was dosed in a...
Medical
Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech
Essex Bio-Technology Limited (the Company, together with its subsidiaries, the Group) wishes to announce that Essex Bio-Investment Limited (Essex Bio-Investment), a wholly-owned subsidiary of...
Medical
Essex Bio-Technology Included in “Forbes Asia’s Best Under A Billion 2022”
Essex Bio-Technology Ltd (EssexBio or the Group, Stock Code: HKG:1061) is pleased and honoured to announce that it is included in "Forbes Asia's 200...
Medical
Essex Bio-Technology Announces 2021 Financial Results
Achieves an increase of 58% in Profit-After-Tax to HK$346.0 million and Turnover Growth of 67.4% to HK$1,637.7 million Essex Bio-Technology Ltd (Essex or the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
